PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

Lipoprotein(a) is thought to contribute to ASCVD through proinflammatory, prothrombotic, and/or other proatherogenic mechanisms. 3, 9 Current evidence suggests that lipoprotein(a) is causal in the ...

Autosomal Dominant Retinitis Pigmentosa . Elucidation of the first genetic basis for ADRP came from the mapping and identification of disease-causing mutations in the rhodopsin gene. [] Since then ...

Independent of etiology, hemolytic diseases are associated with thrombosis, inflammation and immune dysregulation, all together contributing to organ damage and poor outcome. Beyond anemia and the ...

ObjectivesThis study presents four cases of cytomegalovirus retinitis (CMVR) managed using a novel antiviral strategy, ... compound Aic246 (Letermovir) inhibits human cytomegalovirus replication ...

Sidebar: Key Issues Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the ...

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...